Cargando…

Reply letter to “response to article by Johnna Perdrizet et al.” by Gomez and colleagues

This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study “Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perdrizet, Johnna, Santana, Carlos Felipe S., Senna, Thais, Alexandre, Rodrigo Fernandes, Sini de Almeida, Rodrigo, Spinardi, Julia, Wasserman, Matt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Pneumococcal – Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942431/ https://www.ncbi.nlm.nih.gov/pubmed/33908816 http://dx.doi.org/10.1080/21645515.2021.1917237

Ejemplares similares

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
por: Lytle, Derek, et al.
Publicado: (2023)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt
por: Sevilla, JP, et al.
Publicado: (2022)

Pneumonia hospitalizations and mortality in children 3 – 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10)
por: Iliya, Jalo, et al.
Publicado: (2023)

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
por: Ishihara, Yasunori, et al.
Publicado: (2023)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
por: Hammitt, Laura L., et al.
Publicado: (2023)

Regional factors associated with pneumococcal vaccination coverage among U.S. adults with underlying chronic or immunocompromising conditions
por: Liu, Junqing, et al.
Publicado: (2023)

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study
por: Haranaka, Miwa, et al.
Publicado: (2023)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age
por: Chu, Kai, et al.
Publicado: (2023)

A pediatric case series of invasive pneumococcal disease caused by S.Pneumonia serotype-19A despite full dose vaccination
por: Cura Yayla, Burcu Ceylan, et al.
Publicado: (2023)

Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020
por: Guzman-Holst, Adriana, et al.
Publicado: (2021)

Reply to the Letter from Waddell and Colleagues
por: Tuyns, Albert J.
Publicado: (1992)

Reply to the Letter from Waddell and Colleagues
por: Estèeve, J.
Publicado: (1992)

Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media
por: Izurieta, Patricia, et al.
Publicado: (2022)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population
por: Yunhua, Bai, et al.
Publicado: (2022)

Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

REPLY: Reply to Kumar and colleagues
por: Kirklin, James K.
Publicado: (2022)

Dr Adami & colleagues reply
por: Adami, H.-O., et al.
Publicado: (1987)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
por: Hu, Yu, et al.
Publicado: (2022)

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
por: Wang, Wenjuan, et al.
Publicado: (2022)

Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions
por: Edmondson-Jones, Mark, et al.
Publicado: (2021)

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
por: Severance, Randall, et al.
Publicado: (2021)

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
por: Mohanty, Salini, et al.
Publicado: (2022)

The impact of COVID-19 on routine vaccinations in Taiwan and an unexpected surge of pneumococcal vaccination
por: Chiu, Nan-Chang, et al.
Publicado: (2022)

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
por: Lagoubi, Youness, et al.
Publicado: (2022)

Hospitalization costs for children with pneumonia in Shanghai, China from 2019 to 2020
por: Wang, Jing, et al.
Publicado: (2022)

Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 – April 2019
por: Liapikou, Adamantia, et al.
Publicado: (2022)

Economic burden of pneumococcal disease in children in Liguria, Italy
por: Amicizia, Daniela, et al.
Publicado: (2022)

Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine
por: Bhavsar, Amit, et al.
Publicado: (2022)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
por: Sabharwal, Charu, et al.
Publicado: (2022)

Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease
por: Saiphoklang, Narongkorn, et al.
Publicado: (2022)

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial
por: Pan, Lu-Lu, et al.
Publicado: (2022)

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
por: Nymark, Liv Solvår, et al.
Publicado: (2022)

Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review
por: Bencina, Goran, et al.
Publicado: (2022)

Authors’ reply to Quantrill, Benger, Ripley and colleagues, Roach, Rogers, and Haldar and colleagues
por: Wiener, Renda Soylemez, et al.
Publicado: (2013)

Response to the Letter by Spurling and Colleagues
por: Coleman, Craig I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1l3j4q50oflf5n5jl90vl0dnil